Cin-107 is a drug that is used to treat hypertension. It works by blocking an enzyme called aldosterone synthase.
If you have high blood pressure, it can be difficult to get treatment. The medication is approved by the FDA. It is also approved for the treatment of primary aldosteronism.
Cin-107 is a treatment for treatment-resistant hypertension
CIN-107 is an investigational treatment for treatment-resistant hypertension that works by inhibiting the renin-angiotensin system (RAAS), a system that controls fluid and electrolyte balance in the body. Click the link: https://en.wikipedia.org/wiki/Refractory_Hypertension#:~:text=agonists%3B%20or%20Vasodilators.-,Terminology,controlled%20with%20%E2%89%A54%20medications.to learn more about this disease.
The drug is currently being studied in clinical trials in the U.S. and Canada, and its effectiveness in treating hypertension in the treatment-resistant population is unknown.
CinCor Pharma is a clinical-stage biopharmaceutical company that focuses on cardiovascular, metabolic, and renal diseases. The company is currently developing the drug for the treatment of hypertension and primary aldosteronism. The company recently completed a $50 million Series A financing led by Sofinnova Investments and Sofinnova Partners. The funding will be used to advance the development of Cin-107 into clinical trials.
CinCor Pharma's lead program is an oral aldosterone synthase inhibitor (ASI). The drug, licensed from Roche, is an oral aldosterone synthetase inhibitor. Aldosterone is a hormone that increases blood pressure, so blocking this enzyme is important for treating this condition.
This drug is currently being studied in two Phase II trials in people with treatment-resistant hypertension and primary aldosteronism. The company expects to read the results of these studies next year. It also plans to launch two new clinical trials for chronic kidney disease and uncontrolled hypertension.
It is a Phase II aldosterone synthe inhibitor that is gaining traction in clinical trials. The drug is in the early development stages, but the FDA has not approved it yet. Click here for more information about the FDA.
However, it has received positive reviews from clinical trials. The market for this treatment-resistant hypertension drug is growing. The report provides detailed insights into the market for the drug and the key players involved in its development.
The Treatment-resistant Hypertension (RHTN) market is projected to reach over USD 13 billion by 2021 across seven major markets. It also provides an evaluation of the underlying potential, pipeline analysis, and patient population. The report also includes an analysis of the key pipeline drugs, as well as an assessment of unmet needs.
The drug is a highly selective aldosterone synthase inhibitor, which inhibits the synthesis of aldosterone in the adrenal gland. It is currently in Phase 2 clinical trials in patients with uncontrolled hypertension and primary aldosteronism, and the company is anticipating the first readout in 2023.
It blocks an enzyme called aldosterone synthase
CinCor, a biopharmaceutical company, is developing CIN-107, a small molecule that blocks an enzyme that is responsible for the synthesis of aldosterone. The company hopes to use the drug to alleviate the complications of chronic kidney disease and hypertension.
Researchers have found that reducing aldosterone levels can lower blood pressure. However, the current available therapies are not effective enough to help patients lower their blood pressure. Nevertheless, Cin-107 has the potential to significantly improve the treatment of cardio-renal diseases and hypertension. This could help thousands of ill Americans.
The drug is a selective inhibitor of aldosterone synthase that targets the CYP11B2 gene. In addition, it has a low affinity for 11ss-hydroxylase, which is responsible for the synthesis of cortisol. This means that it reduces aldosterone levels without impacting cortisol levels.
Cin-107 is already in clinical trials, including those for chronic kidney disease and uncontrolled hypertension. CinCor recently filed for an IPO, and the company touted the potential of its drug to address these problems. It is a highly selective inhibitor of aldosterone synthase.
Cin-107 was well tolerated in Phase 1 clinical trials, with no serious adverse events or withdrawal of treatment. The company expects to initiate Phase 2 clinical trials for the drug in uncontrolled hypertension. There are currently two other clinical trials underway, one for treatment-resistant hypertension and one for primary aldosteronism.
Clinical trials have also shown that patients with PHA are at a higher risk for cardiovascular events. Furthermore, increased levels of aldosterone were associated with increased mortality in patients with myocardial infarction.
Furthermore, exogenous aldosterone increased infarct size in animal models, and treatment with antagonists of the mineralocorticoid receptor decreased infarct size. The effect was also seen in newly isolated porcine glomerulosa cells.
It affects blood pressure
CinCor, a biopharmaceutical company, is currently conducting a clinical trial of the drug to see how it affects blood pressure. The study involves a number of different patient populations. The primary aim of the trial is to find out whether the drug improves blood pressure by lowering systolic pressure, which is the pressure exerted on the heart during a heartbeat.
The clinical trial is a randomized, double-blind, placebo-controlled, dose-ranging study, which compares the drug to a placebo after 12 weeks in patients with treatment-resistant hypertension. The results from the trial are expected to inform the development of a new drug for hypertension.